Medtech company Onkos Surgical received 510(k) clearance from the FDA for its antibacterial-coated orthopedic implants.
Onkos Surgical’s ELEOS Proximal Tibia with NanoCept Antibacterial Technology prevents intraoperative bacterial contamination during orthopedic implant procedures, according to an Oct. 21 news release from the company.
In preclinical studies, the technology had a 99.999% kill rate of bacteria that are commonly found in operating room environments.
The implants earned the FDA’s De Novo approval in April 2024.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.